Furosemid hydrochlorothiazide
PreclinicalSmall molecule
Furosemid hydrochlorothiazide is one of 12 small molecule programs targeting Dialysis Patients. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Dialysis Patients
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Betadine
BBecton, Dickinson and Company
Approved
Sodium Valproate
AstraZenecaPhase 3
Evrenzo
AstellasPhase 2
KN060
SSuzhou Alphamab Co., Ltd.
Phase 2
Tirosint
IInstitut Jerome Lejeune
Preclinical
Deca-Durabolin
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Tegopen
Bristol-Myers SquibbPreclinical
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Triferic
RRockwell Medical Technologies, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dialysis Patients1 trial
Use of Diuretics in Maintenance Hemodialysis Patients Undergoing Bioimpedance-guided Fluid Management
Unknown status·—·N/A·NCT04182854·46 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCapital Medical University